| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4344786 | Neuroscience Letters | 2012 | 4 Pages |
O-1602 is an atypical cannabinoid that acts as an agonist at GPR55, a g protein-coupled receptor that previous studies have indicated may have a pronociceptive role in neuropathic pain. We administered O-1602 to both naive rats and rats that had undergone chronic constriction injury surgery. O-1602 did not cause any changes in hind paw responses to Von Frey hair testing in naive rats. However, O-1602 reversed the desensitising effects of ETOH, which was used as an active and opposing vehicle. Our results are consistent with the hypothesis that GPR55 has a pronociceptive role in neuropathic pain.
► We test the effect of the atypical cannabinoid O-1602 on neuropathic pain. ► We used the chronic constriction model of neuropathic pain in rats. ► O-1602 did not alter hind paw sensitivity in naïve rats. ► O-1602 reversed the antinociceptive effects of ethanol in neuropathic rats. ► O-1602 is pronociceptive in this model of neuropathic pain.
